Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1

Failure of colorectal cancer (CRC) treatment is due to residual disease, and its timely identification is critical for patient survival. Detecting CRC‐associated mutations in patient circulating cell‐free DNA is confounded by tumor mutation heterogeneity, requiring primary tumor sequencing to identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Symonds, Erin L., Pedersen, Susanne K., Yeo, Bernita, Al Naji, Hiba, Byrne, Susan E., Roy, Amitesh, Young, Graeme P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120880/
https://www.ncbi.nlm.nih.gov/pubmed/35000264
http://dx.doi.org/10.1002/1878-0261.13178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120880/
https://www.ncbi.nlm.nih.gov/pubmed/35000264
http://dx.doi.org/10.1002/1878-0261.13178

Ejemplares similares